Assessing bleeding risk in patients taking anticoagulants

J Thromb Thrombolysis. 2013 Apr;35(3):312-9. doi: 10.1007/s11239-013-0899-7.

Abstract

Anticoagulant medications are commonly used for the prevention and treatment of thromboembolism. Although highly effective, they are also associated with significant bleeding risks. Numerous individual clinical factors have been linked to an increased risk of hemorrhage, including older age, anemia, and renal disease. To help quantify hemorrhage risk for individual patients, a number of clinical risk prediction tools have been developed. These risk prediction tools differ in how they were derived and how they identify and weight individual risk factors. At present, their ability to effective predict anticoagulant-associated hemorrhage remains modest. Use of risk prediction tools to estimate bleeding in clinical practice is most influential when applied to patients at the lower spectrum of thromboembolic risk, when the risk of hemorrhage will more strongly affect clinical decisions about anticoagulation. Using risk tools may also help counsel and inform patients about their potential risk for hemorrhage while on anticoagulants, and can identify patients who might benefit from more careful management of anticoagulation.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Age Factors
  • Anemia / drug therapy
  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use*
  • Female
  • Hemorrhage / chemically induced*
  • Hemorrhage / prevention & control*
  • Humans
  • Kidney Diseases / drug therapy
  • Male
  • Patient Education as Topic*
  • Risk Assessment
  • Risk Factors

Substances

  • Anticoagulants